论文部分内容阅读
目的探讨2型糖尿病患者(T2DM)血清基质金属蛋白酶-2(MMP-2)及其组织抑制因子-1(TIMP-1)在糖尿病高血压、肾损害发病中的作用。方法随机收集T2DM患者64例,其中,无合并症者24例,合并高血压者20例,合并肾病者20例以及健康对照者24例。以ELISA法测定MMP-2、TIMP-1的含量。结果糖尿病患者尤其是合并高血压和肾病患者血清MMP-2明显低于健康对照组(P<0.01),并且随病情发展呈逐渐降低的趋势。而血清TIMP-1随病情的发展则呈现明显升高趋势,无合并症组、合并高血压组和合并肾病组TIMP-1水平明显高于健康对照组(分别为P<0.05,P<0.01和P<0.01)。结论MMP-2和TIMP-1可能参与了糖尿病高血压、肾损害的发生发展过程,对其检测可能为糖尿病及其并发症的早期诊断和治疗提供新的依据。
Objective To investigate the role of serum matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the pathogenesis of hypertension and renal damage in type 2 diabetes mellitus (T2DM). Methods Totally 64 patients with T2DM were randomly selected, including 24 without complications, 20 with hypertension, 20 with nephropathy and 24 healthy controls. The contents of MMP-2 and TIMP-1 were determined by ELISA. Results Serum MMP-2 in patients with diabetes mellitus, especially those with hypertension and nephropathy, was significantly lower than that in healthy controls (P <0.01), and gradually decreased with the progression of the disease. The TIMP-1 level in serum was significantly increased with the progression of the disease. The level of TIMP-1 in non-complication group, combined hypertension group and combined nephropathy group was significantly higher than that in healthy control group (P <0.05, P <0.01 and P <0.01). Conclusion MMP-2 and TIMP-1 may be involved in the pathogenesis of diabetic hypertension and renal damage, which may provide a new basis for the early diagnosis and treatment of diabetes mellitus and its complications.